

DATE:	25 May 2026
TO:	Oncologists, Province Wide
FROM:	Edmonton and Calgary Zone Immunohistochemistry Laboratory, Alberta Precision Laboratories (APL)
RE:	PD-L1 22-C3 Testing for Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Now Available in Alberta

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Oncologists may now submit requests for PD-L1 testing. Eligible malignancies include:
 - Endometrioid carcinoma (any grade)
 - High-grade serous or predominantly serous carcinoma
 - Low-grade serous carcinoma
 - Malignant mixed Müllerian tumors
 - Clear cell carcinoma (ovarian and pelvic mesothelium origin)
- Platinum resistance is defined as radiographic progression within 6 months of the last dose of platinum-based chemotherapy.
- PD-L1 biomarker immunohistochemistry (IHC) testing for platinum-resistant recurrent ovarian cancer is now available using the PD-L1 22C3 PharmDx assay.
- The PD-L1 22C3 PharmDx assay is used to determine eligibility for Pembrolizumab.
- Samples must be formalin-fixed, with an optimal fixation time of 12–72 hours.

Background

- PD-L1 IHC PharmDx 22C3 is the required assay to determine access to Pembrolizumab in patients with the above malignancies, as outlined in the ENGOT-ov65/KEYNOTE-B96 clinical trial.

Action Required

- In Epic, under “Request for Additional Testing for Pathology Sample,” select:
“Ovarian – FT – Primary Peritoneal (from Pelvic Mesothelium) Carcinoma – Pembrolizumab – 22C3.”

Effective May 27, 2026

Questions/Concerns

Calgary:

Dr. Martin Hyrcza

 Martin.Hyrcza@albertaprecisionlabs.ca

 403-944-4759



**ALBERTA PRECISION
LABORATORIES**

Leaders in Laboratory Medicine

Edmonton:

Dr. Gilbert Bigras

 Gilbert.Bigras@albertaprecisionlabs.ca

 780-432-8445

Approved by

- **Dr. Michael Mengel**
Medical Director, North Sector
Alberta Precision Laboratories
- **Dr. Kate O'Connor**
Medical Director, South Sector
Alberta Precision Laboratories